0001209191-18-018991.txt : 20180312
0001209191-18-018991.hdr.sgml : 20180312
20180312195855
ACCESSION NUMBER: 0001209191-18-018991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180308
FILED AS OF DATE: 20180312
DATE AS OF CHANGE: 20180312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dier Mardi
CENTRAL INDEX KEY: 0001574591
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35935
FILM NUMBER: 18684952
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001269021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-244-6864
MAIL ADDRESS:
STREET 1: 270 EAST GRAND AVENUE, SUITE 22
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-08
0
0001269021
PORTOLA PHARMACEUTICALS INC
PTLA
0001574591
Dier Mardi
C/O PORTOLA PHARMACEUTICALS, INC.
270 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive VP and CFO
Common Stock
2018-03-08
4
D
0
10465
38.6875
D
63451
D
Common Stock
2018-03-08
4
D
0
2009
39.1571
D
61442
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $39.02, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4.
This number includes 31,040 unvested RSUs.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.06 to $39.28, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4.
This number includes 31,040 unvested RSUs.
/s/ Mike Ouimette, as attorney-in-fact
2018-03-12